|
Authors
|
McCarthy, J. M. ; Franke, M. ; Resenberger, U. K. ; Waldron, S. ; Simpson, J. C. ; Tatzelt, J. ; Appelhans, D. ; Rogers, M.
|
|
Title
|
Anti-prion drug mPPig inhibits PrPC conversion to PrPSc
|
|
Date
|
13.02.2013
|
|
Number
|
37102
|
|
Abstract
|
Prion diseases, also known as transmissible spongiform encephalopathies, are a group of fatal neurodegenerative diseases that include scrapie in sheep, bovine spongiform encephalopathy (BSE) in cattle and Creutzfeldt-Jakob disease (CJD) in humans. The protein only hypothesis advocates that PrPSc, an abnormal isoform of the cellular protein PrPC, is the main and possibly sole component of prion infectious agents. Currently, no effective therapy exists for these diseases at the symptomatic phase for either humans or animals, though a number of compounds have demonstrated the ability to eliminate PrPSc in cell culture models. Of particular interest are synthetic polymers known as dendrimers which possess the unique ability to eliminate PrPSc in both an intracellular and in vitro setting. The efficacy and mode of action of the novel anti-prion dendrimer mPPIg5 was investigated through the creation of a number of innovative bio-assays based upon the scrapie cell assay. These assays were used to demonstrate that mPPIg5 is a highly effective anti-prion drug which acts, at least in part, through the inhibition of PrPC to PrPSc conversion. Understanding how a drug works is a vital component in maximising its performance. By establishing the efficacy and method of action of mPPIg5, this study will help determine which drugs are most likely to enhance this effect and also aid the design of dendrimers with anti-prion capabilities for the future.
|
|
Publisher
|
PLoS one [Elektronische Ressource]
|
|
Wikidata
|
|
|
Citation
|
PLoS one [Elektronische Ressource] 8 (2013) e55282 [11 pages]
|
|
DOI
|
https://doi.org/10.1371/journal.pone.0055282
|
|
Tags
|
|
